Activity Stream
@moatrx
• 3 weeks ago
Posted a new blog:
US PSORIASIS Competitive Intelligence
US PSORIASIS Competitive Intelligence
Bimekizumab hit PASI 90 in 85% of patients versus 50% for ustekinumab, resetting psoriasis's efficacy bar across six competing mechanisms.
The moderate-to-severe...
